Curti, Brendan D https://orcid.org/0000-0003-3948-2708
Koguchi, Yoshinobu
Leidner, Rom S https://orcid.org/0000-0003-0788-7938
Rolig, Annah S
Sturgill, Elizabeth R
Sun, Zhaoyu
Wu, Yaping
Rajamanickam, Venkatesh
Bernard, Brady
Hilgart-Martiszus, Ian
Fountain, Christopher B
Morris, George
Iwamoto, Noriko
Shimada, Takashi
Chang, ShuChing
Traber, Peter G
Zomer, Eliezer
Horton, J Rex
Shlevin, Harold
Redmond, William L https://orcid.org/0000-0002-2572-1731
Clinical trials referenced in this document:
Documents that mention this clinical trial
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
https://doi.org/10.1136/jitc-2021-002371
8 Universal LCMS-based assay platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics using one reference antibody
https://doi.org/10.1136/jitc-2022-sitc2022.0008
Documents that mention this clinical trial
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
https://doi.org/10.1136/jitc-2021-002371
Documents that mention this clinical trial
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
https://doi.org/10.1136/jitc-2021-002371
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
https://doi.org/10.1136/jitc-2021-002371
Documents that mention this clinical trial
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
https://doi.org/10.1136/jitc-2021-002371
8 Universal LCMS-based assay platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics using one reference antibody
https://doi.org/10.1136/jitc-2022-sitc2022.0008
Documents that mention this clinical trial
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
https://doi.org/10.1136/jitc-2021-002371
8 Universal LCMS-based assay platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics using one reference antibody
https://doi.org/10.1136/jitc-2022-sitc2022.0008
Documents that mention this clinical trial
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
https://doi.org/10.1136/jitc-2021-002371
8 Universal LCMS-based assay platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics using one reference antibody
https://doi.org/10.1136/jitc-2022-sitc2022.0008
Funding for this research was provided by:
Providence Portland Medical Foundation (N/A)
Galectin Therapeutics (N/A)
NIH/NCI (R21CA190790)